Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes in your area.
Trial Scorecard: SOUL
27.23
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
25.13
SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes
22.17
VisualAbstract: Semaglutide Improves Outcomes in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
29.69
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
21.50
💥Soul study group recently shared the result of their study :✔️ Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes @NEJM 🟡 n=9650 🟡 42.4 %had history of CKD 🟡 Majority
20.97
Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an oral GLP-1 drug has been proven to reduce major cardiovascular events The SOUL
22.08
